BMS Q1 2025 Financial Report Interpretation: Despite a 6% Year-on-Year Revenue Decline, Strong Product Portfolio Performance Drives Upward Revision of Full-Year Performance Outlook

On April 24th, Bristol Myers Squibb (BMS) announced its financial results for the first quarter of 2025. Despite facing external challenges such as exchange rate fluctuations, the company's core growth product portfolio performed strongly, driving a significant year-on-year increase in non-GAAP earnings per share (EPS), and prompting an upward revision of its full-year revenue and profit forecasts.

Financial Performance Overview: Growth and Transformation in Parallel

In Q1 2025, Bristol Myers Squibb achieved total revenue of $11.2 billion, a 6% year-on-year decline (a 4% decline when calculated at constant exchange rates). Of this, revenue from the growth product portfolio amounted to $5.6 billion, a 16% year-on-year increase (18% increase at constant exchange rates), serving as the main driver of performance. Meanwhile, revenue from the mature product portfolio declined by 20%, primarily due to competition from generic drugs and changes in U.S. healthcare policy.

Profit Metrics

• GAAP earnings per share (EPS) were $1.20, a significant improvement from the loss of $5.89 in Q1 2024.
• Non-GAAP EPS was $1.80, compared to a loss of $4.40 in the same period last year.

Cost Control

Through strategic productivity programs, sales and marketing expenses (SG&A) decreased by 33% year-on-year (down 20% on a non-GAAP basis), and research and development expenses decreased by 16% year-on-year (down 5% on a non-GAAP basis).

Full-Year Outlook Revision

The company has raised its full-year guidance, now expecting total revenue in the range of $45.8 billion to $46.8 billion (previous guidance was $45.5 billion). Non-GAAP EPS is now expected to be between $6.70 and $7.00 (previously $6.55 to $6.85).

Growth Drivers: Core Products and Emerging Therapies Drive Dual Engines

• Opdivo (nivolumab) global revenue was $2.27 billion (+9%), with its combination therapy with Yervoy (ipilimumab) receiving FDA approval for two additional indications (hepatocellular carcinoma and colorectal cancer), further expanding its market.
• Reblozyl (luspatercept) revenue was $480 million (+35%), becoming an important growth point in the field of hematology.
• Cell therapy Breyanzi (lisocabtagene maraleucel) generated $260 million in revenue (+146%) and heart failure drug Camzyos (mavacamten) earned $160 million (+89%), showcasing the company's continued breakthroughs in innovative therapies.
• It is worth noting that the newly launched product Cobenfy (an adjunctive treatment for schizophrenia) contributed $27 million in revenue despite failing to meet the primary endpoint in the ARISE Phase 3 trial. The company stated it would continue to assess its clinical value.

Challenges and Adjustments: Mature Products Under Pressure, Significant Currency Impact

• In the mature product portfolio, anticoagulant Eliquis (apixaban) generated $3.57 billion in revenue (-4%), mainly due to a decline in sales in the U.S. market.
• Multiple myeloma drug Revlimid (lenalidomide) generated $940 million in revenue (-44%), continuing the impact of generic competition.
• Exchange rate fluctuations had a 4 percentage point negative impact on international revenue. Excluding this factor, international revenue actually grew by 2%.

Research and Development Progress and Regulatory Milestones

In Q1, the company made several key advancements in its pipeline:

• Camzyos received FDA approval for simplified treatment monitoring requirements, improving patient convenience.
• Breyanzi received EU approval for third-line treatment of follicular lymphoma.
• Opdivo's subcutaneous formulation received a recommendation for approval from the European Medicines Agency (EMA), which is expected to improve administration efficiency.
• Sotyktu (deucravacitinib) demonstrated long-term efficacy in a Phase 3 trial for psoriatic arthritis, with robust safety data.

Management Outlook: Focus on Innovation and Efficiency

Dr. Christopher Boerner, Chairman and CEO of Bristol Myers Squibb, stated: "The first-quarter results validate the effectiveness of our growth strategy. By optimizing operations and accelerating pipeline development, we are transforming into a more agile, innovative company." The company emphasized that it will strengthen its leadership in oncology, immunology, and cardiovascular disease through internal research and external collaborations, such as the recent acquisitions of Karuna and RayzeBio.